BioCentury | Apr 15, 2021
Regulation

April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is discontinuing treatment with ICOS agonist feladilimab (GSK3359609) in two Phase II trials for metastatic head and neck squamous cell carcinoma following a recommendation by the independent data monitoring...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Apr 3, 2021
Product Development

Target diversity in the CAR NK and CAR NKT pipeline: Data Byte

Developers of CAR NK and CAR NKT cell therapies for cancer are collectively casting a wide net, with the roughly two dozen programs in development mapping to at least 10 targets across both solid and hematologic tumors....
BioCentury | Mar 27, 2021
Translation in Brief

Lentigen’s trispecific CAR Ts; plus a bispecific antiviral COVID-19 mAb, Wild Biotech, Kancera and more

Researchers from Miltenyi Biotec GmbH’s Lentigen unit created trispecific CAR T cells, dubbed duoCAR T cells, directed against CD19, CD20 and CD22 that eliminated antigen-heterogeneous B cell tumors in...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

Though the failure rate of next-generation checkpoints has far out-stripped that of the rare successes, companies have not been scared away from the search for the next blockbuster, or for a way to finally...
BioCentury | Mar 26, 2021
Regulation

CHMP backs GSK’s lupus drug for kidney complication, J&J’s oral MS therapy

GSK’s Benlysta and J&J’s Ponvory are two of the latest therapies to win support from EMA’s CHMP, which did not issue any negative recommendations in March. The agency recommended a label extension for Benlysta belimumab to treat active lupus...
BioCentury | Mar 25, 2021
Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

Twist Bioscience Corp. (NASDAQ:TWST) said it and partner Biotia Inc. received emergency use authorization from FDA for the first hybridization capture-based next-generation sequencing SARS-CoV-2 assay. The SARS-CoV-2 NGS Assay can sequence and surveil the evolution of virus...
BioCentury | Mar 25, 2021
Product Development

BMS achieves rare next-generation checkpoint win with Phase III LAG3 data

BMS continued its successful run in checkpoint inhibitors with the first example of a Phase III survival benefit among mAbs against next-generation targets, but it will be hard to determine where the therapy may fit...
BioCentury | Mar 23, 2021
Finance

Crossovers invest ahead of pre-IPO round, as bispecifics play EpimAb readies to deploy $120M series C

After raising a $120 million series C round co-led by China Merchants Bank International and Mirae Asset Financial Group, EpimAb now turns to executing on its trio of clinical cancer compounds ahead of a pre-IPO...
BioCentury | Mar 20, 2021
Finance

Dallas TIL play leads Friday IPO trio: Data Byte

Less than three years after its launch, Dallas-based TIL specialist Instil led a trio of NASDAQ debuts late this week. Shares of Instil Bio Inc. (NASDAQ:TIL) rose 32% to $26.44 after raising $320 million in...
Items per page:
1 - 10 of 1479